TLR4 is an attractive therapeutic target of CLD as it is involved in several hepatic inflammatory and fibrotic processes induced by various etiologies, such as NASH and alcoholic liver disease, as well as in animal models of chronic liver injury [29,30,32,33]. Here, TLR4 is linked to metabolic dysfunction-associated steatohepatitis.